![ABLIVA AB [CBOE]](/cache/medias/logo_company/150x80-thumb/sFGlaHAqRUHhzqf.webp?v=1 "ABLIVA AB [CBOE]"){kind=logo}
ABLIVA AB [CBOE] news, videos and press releases
For more news please use our advanced search feature.
ABLIVA AB [CBOE] - More news...
ABLIVA AB [CBOE] - More news...
- Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease
- Abliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Disease on May 21, 2024
- Edison Investment Research Limited: Edison issues update on Abliva (NVP)
- NeuroVive Pharmaceutical AB Year End Report January - December 2019
- NeuroVive Pharmaceutical AB Year End Report January - December 2019
- NeuroVive Pharmaceutical AB Year End Report January - December 2019
- NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study
- NeuroVive Announces Settlement in Dispute With CicloMulsion AG
- NeuroVive Pharmaceutical AB Interim Report January - September 2019
- NeuroVive Pharmaceutical AB Interim Report January - September 2019
- NeuroVive Pharmaceutical AB Interim Report January - September 2019
- NeuroVive Pharmaceutical AB Interim Report January - June 2019
- NeuroVive Pharmaceutical AB Interim Report January - June 2019
- NeuroVive Pharmaceutical AB Interim Report January - June 2019
- Save the Date: NeuroVive to host Capital Markets Day in Stockholm on 9 October, 2019
- NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation
- NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study
- NeuroVive Pharmaceutical AB Interim Report January - March 2019
- NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA
- NeuroVive Pharmaceutical AB Publishes 2018 Annual Report
- NeuroVive Pharmaceutical AB Publishes 2018 Annual Report
- NeuroVive Pharmaceutical AB Publishes 2018 Annual Report
- NeuroVive Enrolls First Subject in its KL1333 Phase Ia/b Clinical Study
- NeuroVive Receives SEK 28.2 Million in a Directed New Share Issue
- NeuroVive Enters Commercial Partnership With Oroboros Instruments on Mitochondrial Medicine Research Compounds
- NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders
- NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders
- NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders
- NeuroVive Receives KL1333 Clinical Trial Regulatory Approval
- Edison Investment Research Limited: Edison issues outlook on NeuroVive Pharmaceutical (NVP)
